Sarnak Mark J
Division of Nephrology, Tufts Medical Center, Boston, Massachusetts
Clin J Am Soc Nephrol. 2014 Oct 7;9(10):1790-8. doi: 10.2215/CJN.11601113. Epub 2014 Apr 24.
There is high prevalence of CKD, defined by reduced GFR, in patients with heart failure. Reduced kidney function is associated with increased morbidity and mortality in this patient population. The cardiorenal syndrome (CRS) involves a bidirectional relationship between the heart and kidneys whereby dysfunction in either may exacerbate the function of the other, but this syndrome has been difficult to precisely define because it has many complex physiologic, biochemical, and hormonal abnormalities. The pathophysiology of CRS is not completely understood, but potential mechanisms include reduced kidney perfusion due to decreased forward flow, increased right ventricular and venous pressure, and neurohormonal adaptations. Treatment options include inotropic medications; diuretics; ultrafiltration; and medications, such as β-blockers, inhibitors of the renin-angiotensin-aldosterone system, and more novel treatments that focus on unique aspects of the pathophysiology. Recent observational studies suggest that treatments that result in a decrease in venous pressure and lead to hemoconcentration may be associated with improved outcomes. Patients with CRS that is not responsive to medical interventions should be considered for ventricular assist devices, heart transplantation, or combined heart and kidney transplantation.
心力衰竭患者中,以肾小球滤过率降低定义的慢性肾脏病(CKD)患病率很高。肾功能降低与该患者群体发病率和死亡率增加相关。心肾综合征(CRS)涉及心脏和肾脏之间的双向关系,即任一器官功能障碍都可能加重另一器官的功能,但该综合征一直难以精确界定,因为它存在许多复杂的生理、生化和激素异常。CRS的病理生理学尚未完全阐明,但潜在机制包括前向血流减少导致的肾脏灌注降低、右心室和静脉压力升高以及神经激素适应性变化。治疗选择包括正性肌力药物;利尿剂;超滤;以及药物,如β受体阻滞剂、肾素 - 血管紧张素 - 醛固酮系统抑制剂,还有专注于病理生理学独特方面的更新型治疗方法。近期观察性研究表明,导致静脉压力降低并引起血液浓缩的治疗可能与改善预后相关。对药物干预无反应的CRS患者应考虑使用心室辅助装置、心脏移植或心脏和肾脏联合移植。